Drugs Made In America Acquisition Corp. DMAA
$10.80
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.79% | -56.69% | 646.52% | 81.99% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.79% | -56.69% | 646.52% | 81.99% | -- |
| Operating Income | -3.79% | 56.69% | -646.52% | -81.99% | -- |
| Income Before Tax | -24.54% | 57.07% | 176.10% | 1,607.66% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.54% | 57.07% | 176.10% | 1,607.66% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.54% | 57.07% | 176.10% | 1,607.66% | -- |
| EBIT | -3.79% | 56.69% | -646.52% | -81.99% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -18.01% | 15.42% | 118.96% | 485.80% | 2,539.29% |
| Normalized Basic EPS | -18.03% | 15.51% | 119.12% | 483.96% | -- |
| EPS Diluted | -18.01% | 18.70% | 118.96% | 426.00% | 2,539.29% |
| Normalized Diluted EPS | -18.03% | 18.89% | 119.12% | 483.96% | -- |
| Average Basic Shares Outstanding | -8.07% | 36.01% | 298.86% | 291.03% | -- |
| Average Diluted Shares Outstanding | -8.07% | 32.18% | 298.86% | 291.03% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |